Q4 2024 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2025-02-06 · accession 0001104659-25-010152
$819.7M
Reported value
13
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $197.0M | 24.0% | 4,896,462 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $188.9M | 23.1% | 8,019,354 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $159.1M | 19.4% | 2,509,456 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $107.0M | 13.1% | 10,402,286 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $81.5M | 9.94% | 6,430,257 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $43.3M | 5.28% | 1,137,149 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $9.9M | 1.21% | 5,836,874 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $8.8M | 1.07% | 8,279,484 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $8.2M | 1.00% | 5,018,178 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $7.2M | 0.88% | 2,092,106 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $4.8M | 0.58% | 1,799,232 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutics, Inc. | $3.6M | 0.44% | 78,447 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $314,413 | 0.04% | 305,255 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.